After chalking up half a dozen tuck-in acquisitions throughout its fiscal year 2021—which ended Sept. 30—BD seems poised to outdo itself in 2022. It’s already …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
